Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Genomic Health, Inc. (NQ: GHDX)
37.24 USD  +0.03 (+0.08%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 21, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Genomic Health, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Today 8:00 EDT
from PR Newswire
Genomic Health Announces Medicare Expanded Coverage Policy for Oncotype DX® Breast Cancer Test to Include Ductal Carcinoma in Situ (DCIS) Diagnosis
May 10, 2013
from PR Newswire
Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Inva
May 08, 2013
Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting Read More
from PR Newswire
Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Inva
May 08, 2013
Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting Read More
from PR Newswire
Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference
May 07, 2013
from PR Newswire
&quot;Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2013 Update&quot; Published
May 07, 2013
from PRBuzz Press Release Distribution
Genomic Health and ECOG-ACRIN Cancer Research Group Announce Publication of Positive DCIS Validation Study in the Journal of the National Cancer Institute
May 02, 2013
Findings Demonstrate Utility of Oncotype DX® to Guide Radiation Treatment Decision for DCIS Patients and Support Expanded Access and Reimbursement Read More
from PR Newswire
Genomic Health Announces First Quarter 2013 Financial Results and Business Progress
May 02, 2013
Product Revenue Increased 8% Compared to Prior Year Read More
from PR Newswire
Genomic Health Announces Investor Webcast and Conference Call to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test on Wednesday, May 8, 2013
May 01, 2013
Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego Read More
from PR Newswire
Genomic Health to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 2, 2013
April 25, 2013
from PR Newswire
Genomic Health Announces Publication of Second Positive Validation of Oncotype DX Colon Cancer Test Confirming Its Value Beyond Conventional Markers
April 17, 2013
Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access Read More
from PR Newswire
Genomic Health to Address One of the Most Significant Needs in Men's Health with the Oncotype DX® Prostate Cancer Test
April 03, 2013
Complete Results from Positive Clinical Validation Study to be Presented at 2013 American Urological Association (AUA) Annual Meeting Read More
from PR Newswire
Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX® Breast Cancer Test
March 15, 2013
New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients Read More
from PR Newswire
Genomic Health Announces Positive Results from Large Study of Oncotype DX® to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Valid
March 13, 2013
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy Read More
from PR Newswire
Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
February 25, 2013
Results Presented at the 14th Annual Advances in Genome Biology and Technology Meeting Reveal Novel Method for RNA-Sequencing and Mutation Identification Read More
from PR Newswire
Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
February 06, 2013
Record 4th Quarter Revenue of $60.4 Million Read More
from PR Newswire
Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013
January 30, 2013
from PR Newswire
Genomic Health Announces New Evidence Further Demonstrating Clinical Utility and Cost-Effectiveness of Oncotype DX in Colon Cancer
January 23, 2013
Data Presented at the 2013 Gastrointestinal Cancers Symposium Show Test Significantly Changes Treatment Decisions, May Reduce Medical Costs While Increasing Patient Well-Being Read More
from PR Newswire
Genomic Health to Present at the J.P. Morgan Healthcare Conference
December 21, 2012
from PR Newswire
Genomic Health Announces Results from Six Studies Demonstrating Unique Value of the Oncotype DX Breast Cancer Test in Early Stage Breast Cancer
December 10, 2012
Clinical Utility and Cost Effectiveness Studies Presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium Support Broader Adoption by Physicians, Patients and Payers Worldwide Read More
from PR Newswire
Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
November 28, 2012
from PR Newswire
Genomic Health to Present at Two Upcoming Investor Conferences
November 09, 2012
from PR Newswire
Genomic Health Announces Third Quarter 2012 Financial Results and Business Progress
November 07, 2012
Product Revenue Increased 13% Compared with Prior Year Read More
from PR Newswire
Genomic Health to Announce Third Quarter 2012 Financial Results and Host Conference Call on Wednesday, November 7, 2012
October 31, 2012
from PR Newswire
Genomic Health Announces Presentation of Three Oncotype DX® Studies in Breast and Colon Cancers at the 2012 European Society for Medical Oncology Congress
September 28, 2012
Large Prospective Study Validates Use of the Oncotype DX test in Stage II and Stage III Colon Cancer and Identifies Genes that May Indicate Effectiveness of Oxaliplatin Read More
from PR Newswire
Genomic Health Announces Positive Topline Results of Large Prostate Cancer Clinical Validation Study; Company to Proceed with 2013 Commercial Launch
September 18, 2012
- Complete Data to be Submitted for Presentation at the 2013 ASCO Genitourinary Cancers Symposium - Read More
from PR Newswire
Station X Closes Second Round of Equity Financing to Accelerate Commercial Launch
September 17, 2012
from GlobeNewswire News Releases
Genomic Health Announces Presentation of Two Oncotype DX® Studies at the 2012 Breast Cancer Symposium
September 13, 2012
New findings reinforce value of Oncotype DX in node-positive breast cancer patients; separate presentation provides background on development of DCIS Score Read More
from PR Newswire
NewBridge Pharmaceuticals Forms Partnership With Genomic Health to Bring Novel Genomic Testing to Patients in Middle East, Africa, and Caspian Regions
August 13, 2012
from Marketwired News Releases
Genomic Health Announces Second Quarter 2012 Financial Results and Business Progress
August 08, 2012
- Product Revenue Increased 13% Compared with Prior Year - Read More
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here